Business

Boehringer Ingelheim Pharmaceuticals has announced the availability of the Stiolto Respimat tiotropium bromide/olodaterol soft mist inhaler in the United States. Stiolto Respimat was approved by the FDA for the treatment of COPD in May 2015. Pharmacies are selling the inhaler for about $325-$350. The company is offering a savings card to cover a co-pays over 12 … [Read more...] about Boehringer Ingelheim launches Stiolto Respimat in the US

US-based Novoteris has received a $2.8 million award from Cystic Fibrosis Foundation Therapeutics Inc. (CFFT) for development of Thiolanox inhaled nitric oxide therapy for the treatment of bacterial lung infections in cystic fibrosis patients. The company said that it plans to use the funding for a Phase 2b study which is expected start by the third quarter of 2015. … [Read more...] about Novoteris gets $2.8 million from Cystic Fibrosis Foundation Therapeutics for inhaled nitric oxide

Alexza Pharmaceuticals has announced that it will suspend production of Adasuve inhaled loxapine for its partners Ferrer and Teva after the third quarter of 2015 "to reduce Alexza's underutilized manufacturing capacity, overhead expenses and related costs, while fulfilling the supply requirements of its commercial partners." The company says that during the … [Read more...] about Alexza to stop manufacturing Adasuve for its partners

Consort Medical, parent company of device maker Bespak, has reported an 84.8% increase in revenue from £100 million in FY 2014 to £184.8 million in FY 2015, an increase it attributes largely to 5.8% growth from Bespak and £79 million in revenues from CDMO Aesica, which Consort acquired in November 2014. The company attributes good part of Bespak's revenue growth … [Read more...] about Consort Medical revenue up 85%

Pulmatrix has issued a series of announcements regarding financing and its trading status on the NASDAQ exchange, a development deal for its PUR0200 inhaled COPD drug, and a new DPI it is developing, using its iSPERSE dry powder technology, for the treatment of pulmonary fungal infections in cystic fibrosis patients. Earlier this year, the company announced that it … [Read more...] about Pulmatrix announces financing, development deal with Mylan, new lead candidate

Milestone Pharmaceuticals has raised $17 million in a Series B financing round, the company said. According to the company, it will use the money for Phase 2 clinical development of MSP-2017, its intranasal calcium channel antagonist for the treatment of paroxysmal supraventricular tachycardia (PSVT). In November 2014, Milestone announced positive Phase 1 results … [Read more...] about Milestone raises $17 million for Phase 2 development of intranasal calcium channel antagonist

Russian pharmaceutical company Nativa announced recently that it has partnered with Italian metering valve manufacturer VARI, a subsidiary of the Lindal Group, for development of metered dose inhaler products. The announcement said that the two companies signed an agreement at CPhI Russia 2015, which took place in April. According to the company's web site, Nativa … [Read more...] about VARI partners with Nativa on MDIs